Vemurafenib*
BRAF+ thyroid
 
BRAF+ adjuvant melanoma
– Combo with MEKi
BRAF+ metastatic melanoma
PLX3397
Hodgkin lymphoma
 
Acute myelogenous lymphoma (AML)
 
Glioblastoma (GBM)
 
Prostate
 
Breast
CNS
PLX5622
Alzheimer’s disease
 
Multiple sclerosis
Autoimmune & Bone
PLX5622
Rheumatoid arthritis


*Co-development with Hoffmann-La Roche Inc.